Phase 3 · Liraglutide

NCT01234649 trial results

Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)

Insulin Secretion-Sensitivity Index (IS-SI) (index), 84 weeks of treatment. Metformin XR Plus Liraglutide: 418.4; Metformin XR Plus Placebo: 333.

Participants
153
Status
completed
Completed
2019-06-14
Sponsor
Woman's

As posted on ClinicalTrials.gov (NCT01234649), updated at source Jul 26, 2019. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT01234649 measured first

Insulin Secretion-Sensitivity Index (IS-SI)index · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
418.4(387)333(206)
Side effects by arm

Side effects in NCT01234649

Percent of participants affected, Data collected over 5 years of trial. The most common events the registry lists.

EventMetformin XR Plus LiraglutideMetformin XR Plus Placebo
Any serious event0%0%
Nausea37.2%2.7%
Diarrhea17.9%17.3%
Allergic reaction to liraglutide1.3%0%
Secondary outcomes

What else it measured

Fasting Blood Glucose (FBG)mg/dL · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
90(6.4)91.7(8.4)
Mean Glucose During OGTT (MBG)mg/dL · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
121.6(20.8)118.8(18.9)
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)index · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
2.2(1.4)2.45(1.5)
Matsuda Insulin Sensitivity Index Derived From OGTTindex · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
5.9(2.9)5.4(3.2)
Insulinogenic Index (IGI) /HOMA-IRindex · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
0.8(1.14)0.62(0.38)
Absolute Body Weightkilograms · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
94.2(18.6)91.3(20)
Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)percent change in weight from baseline · Change from baseline (time 0) to study end (84 weeks) · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
-7.2(1.3)-3.1(1.4)
Body Mass Index (BMI)weight (kg) /height (m) squared · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
33.8(5.2)32.8(6)
Waist Circumference (WC)centimeters · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
94.3(15.2)95.3(15.2)
Waist-to-Hip Ratio (WHR)ratio of waist/hip circumference · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
.81(.04).81(.05)
Waist to Height Ratio (WHtR)ratio of waist /height · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
.56(.08).57(.07)
Total Cholesterol (CHOL) Levelsmg/dL · 84 weeks of treatment · mean
Metformin XR Plus Liraglutiden=35Metformin XR Plus Placebon=37
183.7(36)183.8(27)
The trial

How NCT01234649 was run

A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will develop type 2 diabetes (DM2) at rates much greater than control groups who did not have glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to increase in animal models. This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at-risk overweight/obese women with prior GDM.

  • Metformin XR plus liraglutide: Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
  • Metformin XR plus placebo: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
Who could join the trial

Inclusion Criteria: * Adult female 18 years to 45 years of age who experienced GDM within 52 weeks of index pregnancy * Actual BMI \>25 kg/ m2 * Written consent for participation in the study * Patient completed lactation * Dysglycemia (impaired fasting glucose \[IFG}, impaired glucose tolerance \[IGT} or IFG/IGT) and/or ß-cell dysfunction postpartum requiring pharmacological intervention (except type 1 or 2 diabetes) Exclusion Criteria: Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 * History of pancreatitis * Significant cardiovascular, cerebrovascular, renal, or hepatobiliary diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology) * Serum liver enzymes (AST and/or ALT levels) exceeding more than twice normal laboratory values * Uncontrolled hypertension (systolic blood pressure\>150 mm Hg and/or diastolic blood pressure \>90 mm Hg) * Fasting serum triglycerides ≥800 mg/dl at screening. Lipid-lowering medications must have been maintained at the same dose for 3 months prior to enrollment * Hematological profiles considered to be clinically significant * Cholestasis during the past pregnancy * Presence of contradictions for GLP-1 receptor agonist or metformin administration such as allergy or hypersensitivity * Current use of metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonist medications. * Use of drugs known to exacerbate glucose tolerance. * Use of prescription or over-the-counter weight-loss drugs * Diabetes postpartum or history of diabetes or prior use of medications to treat diabetes except gestational diabetes * Creatinine clearance less than 60 ml/min * History or currently undergoing chemotherapy or radiotherapy for cancer * Pregnancy planned during the coming two years * Currently breastfeeding * Exclusion criteria include any condition, which in the opinion of the investigator would place the subject at increased risk or otherwise make the subject unsuitable for participation in the study

Published papers

Papers from NCT01234649

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.